What is he best known for?
The fields of study he is best known for:
- Immune system
- Cancer
- Gene
His scientific interests lie mostly in Immunology, Immune system, Immunotherapy, Antigen and Virology.
The study incorporates disciplines such as Epitope, Antibody, Dosage form and Vaccination in addition to Immune system.
The Virology study combines topics in areas such as Acquired immune system and Tolerance induction.
He interconnects Cyclophosphamide, B cell, Adoptive cell transfer, Follicular lymphoma and Polyclonal B cell response in the investigation of issues within Chimeric antigen receptor.
His Follicular lymphoma research integrates issues from Survival rate, Cancer research, Oncology and Primary mediastinal B-cell lymphoma.
His research in Refractory Diffuse Large B-Cell Lymphoma intersects with topics in B-cell lymphoma, Chimeric Antigen Receptor T-Cell Therapy and Fludarabine.
His most cited work include:
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma (1549 citations)
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial (477 citations)
- Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma (293 citations)
What are the main themes of his work throughout his whole career to date?
Immunology, Immune system, Antigen, Cancer research and T cell are his primary areas of study.
Adrian Bot works mostly in the field of Immunology, limiting it down to topics relating to Internal medicine and, in certain cases, Gastroenterology, as a part of the same area of interest.
His biological study spans a wide range of topics, including Epitope, Cancer and Virus, Virology.
His Antigen study combines topics in areas such as Antigen-presenting cell, Autoimmunity and Cell biology.
His Cancer research research is multidisciplinary, incorporating elements of B-cell lymphoma, Anti cd19 and CD19.
His T cell study combines topics from a wide range of disciplines, such as Molecular biology, CD8 and B cell.
He most often published in these fields:
- Immunology (48.94%)
- Immune system (34.51%)
- Antigen (23.94%)
What were the highlights of his more recent work (between 2016-2021)?
- Cancer research (17.61%)
- Internal medicine (16.90%)
- T cell (17.25%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Cancer research, Internal medicine, T cell, Chimeric antigen receptor and B-cell lymphoma.
His Cancer research research incorporates elements of Anti cd19, Immune system and Antigen.
His Internal medicine study frequently involves adjacent topics like Oncology.
His study on Chimeric antigen receptor is covered under Immunology.
His B-cell lymphoma research focuses on Refractory and how it relates to CAR T-cell therapy and Long term survival.
He has included themes like Cyclophosphamide and Chimeric Antigen Receptor T-Cell Therapy in his Lymphoma study.
Between 2016 and 2021, his most popular works were:
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma (1549 citations)
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial (477 citations)
- Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma (293 citations)
In his most recent research, the most cited papers focused on:
- Immune system
- Cancer
- Gene
Adrian Bot mainly focuses on Chimeric antigen receptor, Lymphoma, Internal medicine, B-cell lymphoma and Cancer research.
His research investigates the connection between Chimeric antigen receptor and topics such as Antigen that intersect with problems in Adoptive cell transfer.
His work on Fludarabine, Refractory Diffuse Large B-Cell Lymphoma and Refractory as part of general Internal medicine research is frequently linked to Multicenter trial, bridging the gap between disciplines.
His work in Fludarabine addresses subjects such as Chimeric Antigen Receptor T-Cell Therapy, which are connected to disciplines such as Polyclonal B cell response and Survival rate.
The Cancer research study which covers CD19 that intersects with Acute lymphocytic leukemia, K562 cells, Rituximab, Lineage and Toxicity.
The study of Immunology is intertwined with the study of Cyclophosphamide in a number of ways.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
